Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
MetadataShow full item record
BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety. PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC ? T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography. RESULTS: The 10-year DFS rates were 66.5% in the AC ? T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC ? T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC ? T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy. CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC ? T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.
Showing items related by title, author, creator and subject.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 studyAu, H.; Eiermann, W.; Robert, N.; Pienkowski, T.; Crown, J.; Martin, M.; Pawlicki, M.; Chan, Arlene; Mackey, J.; Glaspy, J.; Pintér, T.; Liu, M.; Fornander, T.; Sehdev, S.; Ferrero, J.; Bée, V.; Santana, M.; Miller, D.; Lalla, D.; Slamon, D. (2013)Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and ...
Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, Arlene; Pawlicki, M.; Pinter, T.; Valero, V.; Liu, M.; Sauter, G.; von Minckwitz, G.; Visco, F.; Bee, V.; Buyse, M.; Bendahmane, B.; Tabah-Fisch, I.; Lindsay, M.; Riva, A.; Crown, J.; Breast, C. (2011)Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the ...
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancerChan, Arlene; Willsher, P.; Hastrich, D.; Anderson, J.; Barham, T.; Latham, B.; Redfern, A.; Van der Schaaf, A.; Thomson, J.; Joseph, D.; Ingram, D. (2012)Aims: To assess the feasibility of a standardized multidisciplinary protocol for the management of locally advanced breast cancer (LABC). We also evaluated the accuracy of magnetic resonance imaging (MRI) and positron ...